

Access status of Orphan Drugs (ODs) with trade names with orphan designation in force as of December 31, 2021

OD IN EU AND SPAIN

176
Products with trade name and orphan designation

129
OD with market authorization


111
With National Code in Spain (86%)

56
Financed by the National Health System (43%)

IN 2021

20 New orphan designations in UE

19 New EMA market authorizations




17 OD obtained the National Code in Spain

14 OD financed by the National Health System


OD FINANCED IN SPAIN

% FINANCED

OD with market authorization and financed by the National Health System 2019 - 2021




OD with National Code and financed by the National Health System 2019 - 2021




AVERAGE WAITING TIME

Months elapsed between National Code and entry into the National Health System



OD FINANCED IN 2021 BY THERAPEUTIC AREA




OD UNFINANCED IN SPAIN

55 orphan drugs are waiting for a favorable price and financing resolution

NO. OF UNFINANCED OD PER NATIONAL CODE YEAR



OD UNFINANCED BY THERAPEUTIC AREA



ADVANCED THERAPIES with orphan designation

Currently there are:

- 12 advanced therapies with market authorization in Europe
- 8 with National Code
- 5 financed by the National Health System:

○ 2021: 2 advanced therapies

○ Average waiting time for financing: 21 months

APPROVALS AND FINANCING 2015-2021

